1. Multi-arm Linker Platform：“Bioinorganic site-specific conjugation of multi-arm linkers to create pharmaceuticals with targeting and effector functions” J. Chin. Chem. Soc. 2026, 05 May. (https://doi.org/10.1002/jccs.70204) (Invited Review article, Impact factor: 1.5)
3. TE-1146：“TE-1146, a novel anti-CD38-antibody-lenalidomide conjugate, demonstrates potent ex vivo anti-myeloma activity” Haematologica. 2026, 111(4), 1474-1477. (https://doi.org/10.3324/haematol.2025.288692) (Impact Factor: 7.9, 8th-10th out of ~75-120+ journals in the Hematology category)
5. TE-1146：“An antibody-drug conjugate for multiple myeloma prepared by multi-arm linkers” Adv. Sci. 2024, 2307852. (https://doi.org/10.1002/advs.202307852) (Impact Factor: 14.1, Top 7-8% in Nanoscience & Nanotechnology)
6. ARC：“Site-specific conjugation of 6 DOTA chelators to a CA19-9-targeting scFv-Fc antibody for imaging and therapy” J. Med. Chem. 2023, 66, 10604-10616. (https://doi.org/10.1021/acs.jmedchem.3c00753) (Impact Factor: 6.8, 3rd out of 72 journals in the Medicinal Chemistry category)